Actionable driver events in small cell lung cancer
Fecha
2024Autor
Versión
Acceso abierto / Sarbide irekia
Tipo
Artículo / Artikulua
Versión
Versión publicada / Argitaratu den bertsioa
Identificador del proyecto
Impacto
|
10.3390/ijms25010105
Resumen
Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has already reached a metastatic or extensive stage, leaving chemotherapy as the remaining first-line trea ...
[++]
Small cell lung cancer (SCLC) stands out as the most aggressive form of lung cancer, characterized by an extremely high proliferation rate and a very poor prognosis, with a 5-year survival rate that falls below 7%. Approximately two-thirds of patients receive their diagnosis when the disease has already reached a metastatic or extensive stage, leaving chemotherapy as the remaining first-line treatment option. Other than the recent advances in immunotherapy, which have shown moderate results, SCLC patients cannot yet benefit from any approved targeted therapy, meaning that this cancer remains treated as a uniform entity, disregarding intra- or inter-tumoral heterogeneity. Continuous efforts and technological improvements have enabled the identification of new potential targets that could be used to implement novel therapeutic strategies. In this review, we provide an overview of the most recent approaches for SCLC treatment, providing an extensive compilation of the targeted therapies that are currently under clinical evaluation and inhibitor molecules with promising results in vitro and in vivo. [--]
Materias
Clinical vulnerability,
Heterogeneity,
Inhibitor molecules,
Small cell lung cancer,
Targeted therapy
Editor
MDPI
Publicado en
International Journal of Molecular Sciences 2024, 25(1), 105
Departamento
Universidad Pública de Navarra. Departamento de Ciencias de la Salud /
Nafarroako Unibertsitate Publikoa. Osasun Zientziak Saila
Versión del editor
Entidades Financiadoras
This research was funded by the Spanish Ministry of Science, Innovation, and Universities, grant number PID2019-109577RA-I00/AEI/10.13039/501100011033; the Spanish Ministry of Science, Innovation, and Universities (Ramón y Cajal Program), grant number RYC-2018-023874-I (M.R.); 2021/22 Predoctoral Fellowship UPNA-RYC program (M.G.); the Department of Health, Government of Navarre, grant number 026/2022.